BioMarin Pharmaceutical Inc. (BMRN) — Fair Value Analysis
Base-case fair value (P50): $58.79 · Current price: $55.17 · Verdict: Fairly Valued
The Verdict on BMRN
Based on our comprehensive Monte Carlo simulations, BIOMARIN PHARMACEUTICAL INC (BMRN) is currently deemed Fairly Valued. The analysis indicates a median fair value (P50) of $58.79, standing above its current trading price of $55.17. This suggests a potential +6.6% from current levels, positioning BMRN within a reasonable valuation range rather than being overtly overvalued. Our robust modeling, considering thousands of future scenarios, anchors this assessment, highlighting that while upside exists, it falls within the expected parameters for a company of BMRN's operational and financial profile.
How BMRN stacks up against peers
BMRN holds an average quality tier when assessed against its operational and financial health within the broader market. This average rating implies a balanced risk-reward profile, where its financial stability and operational efficiency are neither outstanding nor concerning compared to industry benchmarks. Despite this average standing, our Monte Carlo analysis still projects a median fair value of $58.79 which sits above the current price of $55.17. This suggests that even with an average quality tier, the market might not fully price in BMRN's intrinsic value, offering a modest +6.6% to investors.
What this means for investors
For investors considering BMRN, the Fairly Valued verdict, coupled with the +6.6% to our median fair value of $58.79 from the $55.17, suggests a balanced outlook. While there isn't a significant undervaluation, the Monte Carlo simulations do not indicate that BMRN is overvalued at its current price. Investors should note the company's average quality tier implies a standard level of operational and financial health. To understand the full range of potential outcomes, including detailed downside and bull-case scenarios from our Monte Carlo distribution, sign up for FairCurve to track BMRN's fair value as new fundamentals are released.
Frequently Asked Questions
Is BMRN overvalued or undervalued right now?
Based on Monte Carlo simulations, BMRN is currently considered fairly valued. Its median fair value (P50) of $58.79 is above its current price of $55.17.
What is the bear case and bull case for BMRN?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is exclusively available with a free FairCurve account. We do not provide these specific figures publicly.
How does FairCurve calculate BMRN's fair value?
FairCurve calculates BMRN's fair value using advanced Monte Carlo simulations, running thousands of forward-looking financial scenarios to derive a comprehensive distribution of potential future values. This rigorous approach provides a probabilistic view of intrinsic value.
How can I track BMRN's fair value as it changes?
You can add BMRN to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts whenever new financial fundamentals, such as earnings reports, are released.